The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
 
Lisa Spees
No Relationships to Disclose
 
Stephanie B. Wheeler
Research Funding - Pfizer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Bradford E. Jackson
No Relationships to Disclose
 
Christopher Baggett
Employment - Rho (I)
 
Lauren E. Wilson
Research Funding - AstraZeneca (Inst)
 
Melissa A. Greiner
Research Funding - Abbott Laboratories (Inst); Novartis (Inst); Philips Healthcare (Inst)
 
Deborah Kaye
Employment - Blue Cross Blue Shield North Carolina (I)
Research Funding - Blue Cross Blue Shield of Michigan
Travel, Accommodations, Expenses - MedReviews
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Physicans' Education Resource; Propella Therapeutics; Sanofi; Vizuri
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Charles D. Scales
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Exelixis (Inst); Merck (Inst); Pfizer (Inst)
 
Jessica Pritchard
Research Funding - Boston Scientific (Inst); Pfizer (Inst); St. Jude Medical (Inst)
 
Michael S. Leapman
Research Funding - BESO Biological (Inst)
 
Cary Philip Gross
Research Funding - AstraZeneca (Inst); Genentech; Johnson & Johnson (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech (Inst)
 
Michaela Ann Dinan
Research Funding - AstraZeneca (Inst)